

# Uwe Siebert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/682044/publications.pdf>

Version: 2024-02-01

351  
papers

20,733  
citations

14124

69  
h-index

13635

134  
g-index

381  
all docs

381  
docs citations

381  
times ranked

25355  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. <i>International Journal of Stroke</i> , 2023, 18, 416-425.	2.9	7
2	Cost-effectiveness analysis of superabsorbent wound dressings in patients with moderate-to-highly exuding leg ulcers in Germany. <i>International Wound Journal</i> , 2022, 19, 447-459.	1.3	7
3	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1311-1321.	2.2	16
4	Determinants of willingness to pay for health services: a systematic review of contingent valuation studies. <i>European Journal of Health Economics</i> , 2022, 23, 1455-1482.	1.4	31
5	Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD). <i>BMJ Open</i> , 2022, 12, e053246.	0.8	11
6	On the role of data, statistics and decisions in a pandemic. <i>AStA Advances in Statistical Analysis</i> , 2022, 106, 349-382.	0.4	14
7	An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply. <i>PLoS ONE</i> , 2022, 17, e0265957.	1.1	2
8	Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions. <i>Atherosclerosis</i> , 2022, 355, 15-29.	0.4	4
9	International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy. <i>Annals of Surgery</i> , 2021, 274, e966-e973.	2.1	20
10	A systematic review of ethical and legal issues in elder care. <i>Nursing Ethics</i> , 2021, 28, 895-910.	1.8	13
11	Barriers Against Prevention Programs for Iodine Deficiency Disorders in Europe: A Delphi Study. <i>Thyroid</i> , 2021, 31, 649-657.	2.4	6
12	Benefits and Harms of a Prevention Program for Iodine Deficiency Disorders: Predictions of the Decision-Analytic EUthyroid Model. <i>Thyroid</i> , 2021, 31, 494-508.	2.4	8
13	The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany. <i>Endocrine Connections</i> , 2021, 10, 1-12.	0.8	5
14	Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 807.	1.0	2
15	New Perspective for Soft Tissue Closure in Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Barbed Sutures. <i>Journal of Clinical Medicine</i> , 2021, 10, 1677.	1.0	1
16	Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities: An Agent-Based Modeling Evaluation. <i>Vaccines</i> , 2021, 9, 434.	2.1	27
17	Economic Evaluation of an N-terminal Pro B-type Natriuretic Peptide-Supported Diagnostic Strategy Among Dyspneic Patients Suspected of Acute Heart Failure in the Emergency Department. <i>American Journal of Cardiology</i> , 2021, 147, 61-69.	0.7	6
18	Evaluation of Contact-Tracing Policies against the Spread of SARS-CoV-2 in Austria: An Agent-Based Simulation. <i>Medical Decision Making</i> , 2021, 41, 1017-1032.	1.2	25

#	ARTICLE	IF	CITATIONS
19	Non-mass Enhancement in Breast MRI: Characterization with BI-RADS Descriptors and ADC Values. <i>SciMedicine Journal</i> , 2021, 3, 77-87.	1.5	6
20	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. <i>European Journal of Health Economics</i> , 2021, 22, 1311-1344.	1.4	18
21	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. <i>Blood Advances</i> , 2021, , .	2.5	6
22	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. <i>Annals of Hematology</i> , 2021, 100, 2921-2932.	0.8	7
23	Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. <i>Medical Decision Making</i> , 2021, , 0272989X21110262.	1.2	0
24	RE: "EFFECT ESTIMATES IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES: COMPARING APPLES WITH APPLES" American Journal of Epidemiology, 2020, 189, 77-78.	1.6	7
25	Reducing overtreatment associated with overdiagnosis in cervical cancer screening "A model-based benefit-harm analysis for Austria. <i>International Journal of Cancer</i> , 2020, 147, 1131-1142.	2.3	13
26	Epidemiology of status epilepticus in adults: Apples, pears, and oranges " A critical review. <i>Epilepsy and Behavior</i> , 2020, 103, 106720.	0.9	32
27	Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis. <i>Journal of Strength and Conditioning Research</i> , 2020, 34, 2697-2707.	1.0	18
28	Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer "A Systematic Review. <i>Cancers</i> , 2020, 12, 1874.	1.7	9
29	Status epilepticus admissions during the COVID-19 pandemic in Salzburg "A population-based study. <i>Epilepsia</i> , 2020, 61, e198-e203.	2.6	11
30	Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. <i>Journal of Medical Economics</i> , 2020, 23, 1061-1071.	1.0	12
31	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e036102.	0.8	17
32	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
33	Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020, 2020, CD013574.	1.5	168
34	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	3.8	180
35	Development of a core outcome set for myelodysplastic syndromes " a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
36	Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR. <i>BMC Gastroenterology</i> , 2020, 20, 131.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Effects of Motorcycle Noise on Annoyance—A Cross-Sectional Study in the Alps. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1580.	1.2	6
38	Infants and mothers levels of mercury in breast milk, urine and hair, data from an artisanal and small-scale gold mining area in Kadoma / Zimbabwe. <i>Environmental Research</i> , 2020, 184, 109266.	3.7	18
39	Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. <i>European Journal of Haematology</i> , 2020, 104, 476-487.	1.1	25
40	Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview. <i>Thyroid</i> , 2020, 30, 746-758.	2.4	8
41	Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020, 4, CD013574.	1.5	571
42	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. <i>Value in Health</i> , 2020, 23, 529-539.	0.1	59
43	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1754-1759.	2.9	17
44	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. <i>Cancer Prevention Research</i> , 2020, 13, 429-442.	0.7	10
45	<i>Pharmacoeconomics</i> , 2020, , 1-135.		0
46	Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia. <i>Zdravstveno Varstvo</i> , 2020, 59, 83-91.	0.6	1
47	Economic burden of stroke: a systematic review on post-stroke care. <i>European Journal of Health Economics</i> , 2019, 20, 107-134.	1.4	300
48	Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2475-2493.	0.7	23
49	Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness. <i>Medical Decision Making</i> , 2019, 39, 509-522.	1.2	2
50	Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 23.	0.6	5
51	Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review. <i>BMC Health Services Research</i> , 2019, 19, 737.	0.9	26
52	Why should we apply ABM for decision analysis for infectious diseases?—An example for dengue interventions. <i>PLoS ONE</i> , 2019, 14, e0221564.	1.1	19
53	Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. <i>Value in Health Regional Issues</i> , 2019, 20, 95-102.	0.5	2
54	&lt;p&gt;The Optimizing-Risk-Communication (OptRisk) randomized trial &ndash; impact of decision-aid-based consultation on adherence and perception of cardiovascular risk&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 441-452.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Budget Impact Analysis of Cancer Screening: A Methodological Review. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 493-511.	1.0	6
56	Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. <i>BMC Medical Research Methodology</i> , 2019, 19, 69.	1.4	12
57	Prevention of Cervical Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 160-176.	0.8	26
58	Prevention of Cervical Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 148-159.	0.8	19
59	Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1013-1025.	0.6	9
60	Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. <i>BMC Gastroenterology</i> , 2019, 19, 209.	0.8	13
61	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019, 22, 13-20.	0.1	76
62	Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. <i>Epilepsia</i> , 2019, 60, 53-62.	2.6	151
63	Costs of sequential multiple myeloma treatment for elderly transplant-ineligible patients in the Serbian health care system. <i>Medicinski Pregled</i> , 2019, 72, 88-97.	0.1	2
64	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	12.5	129
65	Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach. <i>European Journal of Health Economics</i> , 2018, 19, 1229-1242.	1.4	7
66	Recommendations for primary studies evaluating therapeutic medical devices were identified and systematically reported through reviewing existing guidance. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 46-58.	2.4	9
67	Mediator Effect of Balance Problems on Association Between Grip Strength and Falls in Older Adults: Results From the KORA-Age Study. <i>Gerontology and Geriatric Medicine</i> , 2018, 4, 233372141876012.	0.8	13
68	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. <i>Genetics in Medicine</i> , 2018, 20, 132-141.	1.1	36
69	Ten recommendations for assessing the comparative effectiveness of therapeutic medical devices: a targeted review and adaptation. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 97-113.	2.4	9
70	Health state utilities among contemporary prostate cancer patients on active surveillance. <i>Translational Andrology and Urology</i> , 2018, 7, 197-202.	0.6	3
71	Cost utility of fractional flow reserve-guided percutaneous coronary intervention in multivessel coronary artery disease in Brazil. <i>International Journal for Quality in Health Care</i> , 2018, 31, 676-681.	0.9	1
72	Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. <i>MDM Policy and Practice</i> , 2018, 3, 238146831775192.	0.5	1

#	ARTICLE	IF	CITATIONS
73	Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. <i>PLoS ONE</i> , 2018, 13, e0204643.	1.1	7
74	To stop or not to stop: a value of information view. <i>European Journal of Epidemiology</i> , 2018, 33, 785-787.	2.5	0
75	How Do We Improve the Impact of Iodine Deficiency Disorders Prevention in Europe and Beyond?. <i>European Thyroid Journal</i> , 2018, 7, 193-200.	1.2	15
76	Systematic assessment of decision-analytic models evaluating diagnostic tests for acute myocardial infarction based on cardiac troponin assays. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 619-640.	0.7	3
77	Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer. <i>Value in Health</i> , 2018, 21, S18.	0.1	0
78	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes – a Delphi Survey from the European-MDS Registry. <i>Blood</i> , 2018, 132, 2295-2295.	0.6	0
79	A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. <i>Health Economics (United Kingdom)</i> , 2017, 26, 46-69.	0.8	21
80	Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 333-351.	1.0	19
81	Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1567-1578.	0.4	27
82	Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria. <i>Breast</i> , 2017, 33, 178-182.	0.9	10
83	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. <i>European Urology</i> , 2017, 72, 899-907.	0.9	23
84	Development of a novel prognostic score for breast cancer patients using mRNA expression of <i>CHAC1</i> . <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 563-574.	0.6	7
85	The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria. <i>Value in Health</i> , 2017, 20, 1048-1057.	0.1	21
86	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	1.2	12
87	Personalized medicine in Europe: not yet personal enough?. <i>BMC Health Services Research</i> , 2017, 17, 289.	0.9	37
88	Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. <i>BMC Cancer</i> , 2017, 17, 685.	1.1	14
89	Signs and symptoms of mercury-exposed gold miners. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2017, 30, 249-269.	0.6	38
90	TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 160-166.	0.2	26

#	ARTICLE	IF	CITATIONS
91	Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 196-204.	1.9	7
92	USING EXPERT OPINION IN HEALTH TECHNOLOGY ASSESSMENT: A GUIDELINE REVIEW. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 131-139.	0.2	9
93	Gender differences in the association between grip strength and mortality in older adults: results from the KORA-age study. <i>BMC Geriatrics</i> , 2016, 16, 201.	1.1	70
94	The Use Of Administrative Data To Determine Prevalence And Incidence Of Copd: A Systematic Review. <i>Value in Health</i> , 2016, 19, A368-A369.	0.1	2
95	Cost-Effectiveness of Different Cervical Cancer Primary Screening Using Cytology, HPV Or P16/KI-67 Testing Alone Or in Combinations for The Austrian Health Care Context. <i>Value in Health</i> , 2016, 19, A694.	0.1	1
96	A preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia. <i>Environmental Research</i> , 2016, 149, 274-281.	3.7	70
97	Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications. <i>Movement Disorders</i> , 2016, 31, 1183-1191.	2.2	39
98	Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention – does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 152.	1.5	12
99	Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. <i>European Journal of Public Health</i> , 2016, 26, 498-505.	0.1	4
100	Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation-independent of absolute altitude?. <i>Sleep and Breathing</i> , 2016, 20, 435-442.	0.9	20
101	Ensuring Effective Prevention of Iodine Deficiency Disorders. <i>Thyroid</i> , 2016, 26, 189-196.	2.4	30
102	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. <i>Medical Decision Making</i> , 2016, 36, 375-390.	1.2	6
103	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. <i>Pharmacoeconomics</i> , 2016, 34, 227-244.	1.7	97
104	Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. <i>PLoS ONE</i> , 2016, 11, e0147381.	1.1	15
105	Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011. <i>PLoS ONE</i> , 2016, 11, e0153106.	1.1	63
106	Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review. <i>Epidemiology and Infection</i> , 2015, 143, 1791-1802.	1.0	17
107	The ONCOTYROL Prostate Cancer Outcome and Policy Model. <i>Medical Decision Making</i> , 2015, 35, 758-772.	1.2	8
108	Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. <i>SpringerPlus</i> , 2015, 4, 752.	1.2	10



#	ARTICLE	IF	CITATIONS
109	Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. <i>Journal of Personalized Medicine</i> , 2015, 5, 470-486.	1.1	81
110	Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis. <i>Leukemia Research and Treatment</i> , 2015, 2015, 1-12.	2.0	16
111	TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A META-ANALYSIS AND INDIRECT TREATMENT COMPARISON. <i>Value in Health</i> , 2015, 18, A432.	0.1	1
112	Concepts of "Personalization"™ in Personalized Medicine: Implications for Economic Evaluation. <i>Pharmacoeconomics</i> , 2015, 33, 49-59.	1.7	59
113	Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 164-178.	2.0	11
114	The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 21-33.	1.0	25
115	Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck. <i>Urologia Internationalis</i> , 2015, 94, 419-427.	0.6	14
116	Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. <i>Clinical Research in Cardiology</i> , 2015, 104, 304-309.	1.5	13
117	Systematic overview of cost-effectiveness thresholds in ten countries across four continents. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 485-504.	0.6	92
118	Oncotyrol " Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2015, 109, 330-340.	0.7	7
119	Health technology assessment of medical devices: What is different? An overview of three European projects. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2015, 109, 309-318.	0.7	37
120	Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision-Makers. <i>Health Economics (United Kingdom)</i> , 2015, 24, 481-490.	0.8	20
121	Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2315-2325.	0.6	19
122	Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 13-19.	0.7	20
123	Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2014, 50, 345-352.	1.2	1
124	The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates. <i>Environmental Health</i> , 2014, 13, 111.	1.7	48
125	BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. <i>European Journal of Epidemiology</i> , 2014, 29, 777-790.	2.5	83
126	Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2014, 17, 99-110.	1.0	5



#	ARTICLE	IF	CITATIONS
127	Medical decision analysis for first-line therapy of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1758-1767.	0.6	4
128	Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. <i>Heart Lung and Circulation</i> , 2014, 23, 527-533.	0.2	27
129	Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. <i>International Journal of Public Health</i> , 2014, 59, 175-187.	1.0	1
130	Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 103-115.	1.0	8
131	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. <i>Clinical Infectious Diseases</i> , 2014, 58, 1064-1071.	2.9	34
132	A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18509-e18509.	0.8	0
133	Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 35.	1.0	18
134	Effects of resistance training on respiratory function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2013, 17, 217-226.	0.9	30
135	When is enough evidence enough? â€œ Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2013, 107, 575-584.	0.7	26
136	Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 572-574.	8.2	2
137	Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation. <i>European Journal of Health Economics</i> , 2013, 14, 1035-1048.	1.4	2
138	ISPOR-SMDM Task Force's Recommendations for Good Modeling Practicesâ€”Reply to Letter to the Editor by Corro Ramos. <i>Value in Health</i> , 2013, 16, 1108.	0.1	2
139	Framework for Evidence Assessment Based on Grade and Application to HPV Vaccination in Males in the European Health Care Context. <i>Value in Health</i> , 2013, 16, A327.	0.1	0
140	885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215). <i>Journal of Hepatology</i> , 2013, 58, S364.	1.8	2
141	Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 763-771.	2.2	79
142	Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 847-855.	0.9	49
143	Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 790-797.	0.8	31
144	Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. <i>PLoS ONE</i> , 2013, 8, e82967.	1.1	51

#	ARTICLE	IF	CITATIONS
145	Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma. <i>Blood</i> , 2013, 122, 2991-2991.	0.6	0
146	Personalisierte Krebstherapie. <i>PharmacoEconomics - German Research Articles</i> , 2012, 10, 87-104.	0.1	0
147	Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary prevention patients using statins. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 109-117.	0.8	6
148	State-Transition Modeling. <i>Medical Decision Making</i> , 2012, 32, 690-700.	1.2	231
149	Modeling Good Research Practices“Overview. <i>Medical Decision Making</i> , 2012, 32, 667-677.	1.2	389
150	Cost“effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. <i>Pharmacogenomics</i> , 2012, 13, 1405-1417.	0.6	17
151	Economic burden of osteoporotic fractures in Austria. <i>Health Economics Review</i> , 2012, 2, 12.	0.8	29
152	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
153	Modeling Good Research Practices“Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. <i>Value in Health</i> , 2012, 15, 796-803.	0.1	481
154	State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. <i>Value in Health</i> , 2012, 15, 812-820.	0.1	336
155	PIN90 Towards Best Practices for Handling Uncertainties in Health Technology Assessments for HPV Vaccination to Better Inform Decision Making. <i>Value in Health</i> , 2012, 15, A401-A402.	0.1	0
156	Challenges in the Development and Reimbursement of Personalized Medicine“Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. <i>Value in Health</i> , 2012, 15, 1162-1171.	0.1	119
157	PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy. <i>Value in Health</i> , 2012, 15, A209.	0.1	0
158	Principles for planning and conducting comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 431-440.	0.6	16
159	An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System. <i>Value in Health Regional Issues</i> , 2012, 1, 129-135.	0.5	10
160	Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 457-463.	2.2	5
161	CAN WE RELIABLY BENCHMARK HEALTH TECHNOLOGY ASSESSMENT ORGANIZATIONS?. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 159-165.	0.2	30
162	Resistance training, visceral obesity and inflammatory response: a review of the evidence. <i>Obesity Reviews</i> , 2012, 13, 578-591.	3.1	87

#	ARTICLE	IF	CITATIONS
163	Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. <i>International Journal of Public Health</i> , 2012, 57, 57-62.	1.0	39
164	Effect of guideline orientation on the outcomes of peripheral arterial disease in primary care. <i>Current Medical Research and Opinion</i> , 2011, 27, 1183-1190.	0.9	4
165	Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure. <i>Pharmacoeconomics</i> , 2011, 29, 753-769.	1.7	31
166	Modelling the Cost Effectiveness of Treatments for Parkinson's Disease. <i>Pharmacoeconomics</i> , 2011, 29, 1025-1049.	1.7	26
167	OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. <i>Digestive and Liver Disease</i> , 2011, 43, S70.	0.4	5
168	Fractional Flow Reserve in Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1183-1189.	1.1	158
169	PHP124 Personalized Decision Making in Cancer Medicine? Systematic Overview of HTA Procedures and Specific Approaches in Ten Countries Across Four Continents. <i>Value in Health</i> , 2011, 14, A355-A356.	0.1	0
170	Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis. <i>European Journal of Cancer</i> , 2011, 47, 1633-1646.	1.3	34
171	Costs of illness and care in Parkinson's Disease: An evaluation in six countries. <i>European Neuropsychopharmacology</i> , 2011, 21, 180-191.	0.3	84
172	Indirect treatment comparison of bevacizumab + interferon- $\alpha$ -2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 19.	0.7	5
173	Human Biomonitoring Data from Mercury Exposed Miners in Six Artisanal Small-Scale Gold Mining Areas in Asia and Africa. <i>Minerals (Basel, Switzerland)</i> , 2011, 1, 122-143.	0.8	36
174	Mercury exposure in female artisanal small-scale gold miners (ASGM) in Mongolia: An analysis of human biomonitoring (HBM) data from 2008. <i>Science of the Total Environment</i> , 2011, 409, 994-1000.	3.9	52
175	Introduction of organised mammography screening in Tyrol: results following first year of complete rollout. <i>BMC Public Health</i> , 2011, 11, 673.	1.2	13
176	Applicability of two mobile analysers for mercury in urine in small-scale gold mining areas. <i>International Journal of Hygiene and Environmental Health</i> , 2011, 215, 64-67.	2.1	9
177	Introduction of organised mammography screening in tyrol: results of a one-year pilot phase. <i>BMC Public Health</i> , 2011, 11, 91.	1.2	9
178	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2011, 27, 2193-2201.	0.9	3
179	Do women with cancer have better survival as compared to men after adjusting for staging distribution?. <i>European Journal of Public Health</i> , 2011, 21, 387-391.	0.1	20
180	Individual health services. <i>GMS Health Technology Assessment</i> , 2011, 7, Doc05.	2.2	3

#	ARTICLE	IF	CITATIONS
181	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010, 11, 989-1002.	0.6	26
182	Intravascular ultrasound radiofrequency analysis of the lesion segment profile in ACS patients. <i>Clinical Research in Cardiology</i> , 2010, 99, 83-91.	1.5	13
183	Outcomes of medical management of peripheral arterial disease in general practice: follow-up results of the PACE-PAD Study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2010, 18, 523-532.	0.8	0
184	Health assessment of artisanal gold miners in Tanzania. <i>Science of the Total Environment</i> , 2010, 408, 796-805.	3.9	81
185	Health assessment of artisanal gold miners in Indonesia. <i>Science of the Total Environment</i> , 2010, 408, 713-725.	3.9	111
186	Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening. <i>BMC Public Health</i> , 2010, 10, 86.	1.2	11
187	Vision and challenges of Evidence-Based Health Informatics: A case study of a CPOE meta-analysis. <i>International Journal of Medical Informatics</i> , 2010, 79, e83-e88.	1.6	26
188	The efficiency frontier approach to economic evaluation of health-care interventions. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1117-1127.	0.8	97
189	IQWiG methods – a response to two critiques. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1137-1138.	0.8	8
190	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	2.2	205
191	Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation. <i>Value in Health</i> , 2010, 13, 501-506.	0.1	15
192	Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 34-50.	1.0	32
193	EBM, HTA, and CER: Clearing the Confusion. <i>Milbank Quarterly</i> , 2010, 88, 256-276.	2.1	140
194	Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss's Error Propagation, an Alternative to Established Methods. <i>Medical Decision Making</i> , 2010, 30, 304-313.	1.2	16
195	Markov Processes for the Prediction of Aircraft Noise Effects on Sleep. <i>Medical Decision Making</i> , 2010, 30, 275-289.	1.2	5
196	Evaluating HTA principles. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 429-430.	0.2	2
197	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 71-78.	0.2	52
198	Economic Evaluation of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Multivessel Disease. <i>Circulation</i> , 2010, 122, 2545-2550.	1.6	332

#	ARTICLE	IF	CITATIONS
199	C-Reactive Protein Levels and Post-ICU Mortality in Nonsurgical Intensive Care Patients. <i>Chest</i> , 2010, 138, 856-862.	0.4	33
200	Benefit, Risks and Cost-Effectiveness of Screening for Abdominal Aortic Aneurysm. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2010, 182, 573-580.	0.7	21
201	Resistance Training in the Treatment of the Metabolic Syndrome. <i>Sports Medicine</i> , 2010, 40, 397-415.	3.1	191
202	Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 177-184.	1.2	990
203	A network against failing heartsâ€”Introducing the German â€œCompetence Network Heart Failureâ€”. <i>International Journal of Cardiology</i> , 2010, 145, 135-138.	0.8	39
204	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, S4-S10.	0.9	17
205	CN4 HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC MODELING STUDY. <i>Value in Health</i> , 2010, 13, A239.	0.1	1
206	PCN161 DECISION-ANALYTIC MODELING IN CHRONIC MYELOID LEUKEMIAâ€”A SYSTEMATIC OVERVIEW. <i>Value in Health</i> , 2010, 13, A281-A282.	0.1	0
207	Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 30-39.	0.2	16
208	Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Oncologist</i> , 2010, 15, 1179-1191.	1.9	63
209	Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. <i>GMS Health Technology Assessment</i> , 2010, 6, Doc05.	2.2	12
210	GesundheitsÃkonomische Bewertungen. , 2010, , 557-573.		0
211	Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 305-314.	0.2	44
212	Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection. <i>European Journal of Public Health</i> , 2009, 19, 245-253.	0.1	49
213	Decision-Analytic Modeling to Evaluate Benefits and Harms of Medical Tests: Uses and Limitations. <i>Medical Decision Making</i> , 2009, 29, E22-E29.	1.2	73
214	Are survival rates for Tyrol published in the Eurocare studies biased?. <i>Acta OncolÃ³gica</i> , 2009, 48, 984-991.	0.8	19
215	The German Coronary Artery Disease Risk Screening Model: Development, Validation, and Application of a Decision-Analytic Model for Coronary Artery Disease Prevention with Statins. <i>Medical Decision Making</i> , 2009, 29, 619-633.	1.2	9
216	HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. <i>BMC Public Health</i> , 2009, 9, 34.	1.2	188

#	ARTICLE	IF	CITATIONS
217	Reply to the letter to the editor by J.G. D'Área "Health hazard for infants: Breast-milk mercury or non-breastfeeding? A dilemma for mothers exposed to mercury vapours". International Journal of Hygiene and Environmental Health, 2009, 212, 235-237.	2.1	1
218	Presentation and medical management of peripheral arterial disease in general practice: rationale, aims, design and baseline results of the PACE-PAD Study. Zeitschrift Fur Gesundheitswissenschaften, 2009, 17, 127-135.	0.8	4
219	Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations: A Technical Note. Value in Health, 2009, 12, 96-97.	0.1	4
220	Utility Estimates for Decision "Analytic Modeling in Chronic Heart Failure" Health States Based on New York Heart Association Classes and Number of Rehospitalizations. Value in Health, 2009, 12, 185-187.	0.1	98
221	Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report "Part II. Value in Health, 2009, 12, 1052-1061.	0.1	246
222	Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report "Part III. Value in Health, 2009, 12, 1062-1073.	0.1	234
223	Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine, 2009, 27, 5133-5141.	1.7	49
224	Die Bewertung der KosteneffektivitÄt von Impfungen unter BerÄcksichtigung von Public Health Aspekten. Public Health Forum, 2009, 17, 9-11.	0.1	1
225	Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response. Pharmacoeconomics, 2009, 27, 341-354.	1.7	26
226	Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention. New England Journal of Medicine, 2009, 360, 213-224.	13.9	3,510
227	PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). Value in Health, 2009, 12, A258.	0.1	0
228	Coronary plaque dimensions and composition by intravascular ultrasound radio frequency lesion segment analysis in stable and unstable angina patients. Coronary Artery Disease, 2009, 20, 309-316.	0.3	2
229	Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events. GMS Health Technology Assessment, 2009, 5, Doc06.	2.2	4
230	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. Value in Health, 2008, 11, 539-544.	0.1	138
231	Mercury in breast milk " A health hazard for infants in gold mining areas?. International Journal of Hygiene and Environmental Health, 2008, 211, 615-623.	2.1	68
232	HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES. Value in Health, 2008, 11, A337-A338.	0.1	2
233	PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING "A SYSTEMATIC REVIEW. Value in Health, 2008, 11, A437-A438.	0.1	0
234	Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care, 2008, 24, 244-258.	0.2	356



#	ARTICLE	IF	CITATIONS
235	The Munich Score: A Clinical Index to Predict Survival in Ambulatory Patients With Chronic Heart Failure in the Era of New Medical Therapies. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 222-228.	0.3	19
236	Assessment and Characterization of Time-related Differences in Plaque Composition by Intravascular Ultrasound-derived Radiofrequency Analysis in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 302-309.	0.3	24
237	Market uptake of new antiviral drugs for the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2008, 49, 528-536.	1.8	83
238	Mercury as a serious health hazard for children in gold mining areas. <i>Environmental Research</i> , 2008, 107, 89-97.	3.7	175
239	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. <i>European Journal of Radiology</i> , 2008, 65, 449-461.	1.2	156
240	The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic Review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2008, 15, 585-600.	2.2	537
241	Decision-analytic models for breast cancer: Do currently published models meet the requirements of personalized medicine?. , 2008, , .		0
242	Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 1026-1032.	2.9	26
243	Progression-free survival as a surrogate endpoint in advanced breast cancer. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 371-383.	0.2	82
244	Response from the authors of "Key principles for the improved conduct of health technology assessments for resource allocation decisions". <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 367-368.	0.2	5
245	Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 184-192.	0.2	18
246	Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity. <i>GMS Health Technology Assessment</i> , 2008, 4, Doc03.	2.2	0
247	Measurement of fractional flow reserve to guide decisions for percutaneous coronary intervention. <i>GMS Health Technology Assessment</i> , 2008, 4, Doc07.	2.2	0
248	Health and environmental training in mercury-contaminated areas. <i>International Journal of Environment and Health</i> , 2007, 1, 621.	0.3	10
249	Health-related quality of life in patients with narcolepsy. <i>Sleep Medicine</i> , 2007, 8, 733-741.	0.8	134
250	Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: Serial angiographic and sonographic analysis. <i>American Heart Journal</i> , 2007, 153, 979.e1-979.e8.	1.2	21
251	Rationale and design of the fractional flow reserve versus angiography for multivessel evaluation (FAME) study. <i>American Heart Journal</i> , 2007, 154, 632-636.	1.2	78
252	Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. <i>Journal of Hepatology</i> , 2007, 47, 270-276.	1.8	100



#	ARTICLE	IF	CITATIONS
253	Rate of clinical progression in Parkinson's disease. A prospective study. <i>Movement Disorders</i> , 2007, 22, 938-945.	2.2	129
254	Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy. <i>European Radiology</i> , 2007, 17, 2384-2393.	2.3	19
255	Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical. <i>GMS Health Technology Assessment</i> , 2007, 3, Doc08.	2.2	1
256	Intravascular Optical Coherence Tomography: Comparison with Histopathology in Atherosclerotic Peripheral Artery Specimens. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 343-349.	0.2	52
257	A Systematic Meta-Analysis of the Efficacy and Heterogeneity of Disease Management Programs in Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, 554-567.	0.7	151
258	A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. <i>American Heart Journal</i> , 2006, 151, 48-54.	1.2	63
259	Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort—Consequences for progression studies. <i>European Journal of Radiology</i> , 2006, 57, 396-402.	1.2	103
260	Cost-Effectiveness of Using N-Terminal Pro-Brain Natriuretic Peptide to Guide the Diagnostic Assessment and Management of Dyspneic Patients in the Emergency Department. <i>American Journal of Cardiology</i> , 2006, 98, 800-805.	0.7	88
261	The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany. <i>European Journal of Public Health</i> , 2006, 16, 185-192.	0.1	62
262	Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. <i>European Heart Journal</i> , 2006, 27, 1465-1471.	1.0	163
263	Diagnostic Performance of Stress Perfusion and Delayed-Enhancement MR Imaging in Patients with Coronary Artery Disease. <i>Radiology</i> , 2006, 240, 39-45.	3.6	99
264	Cardiac CT in Emergency Department Patients with Acute Chest Pain. <i>Radiographics</i> , 2006, 26, 963-978.	1.4	55
265	Long-Term Outcome After Stroke. <i>Stroke</i> , 2006, 37, 193-198.	1.0	233
266	Case finding for hepatitis C in primary care: a cost utility analysis. <i>Family Practice</i> , 2006, 23, 393-406.	0.8	28
267	The cost-effectiveness of testing for hepatitis C in former injecting drug users. <i>Health Technology Assessment</i> , 2006, 10, iii-iv, ix-xii, 1-93.	1.3	56
268	Extracorporeal hemodialysis with acute or decompensated chronic hepatic failure. <i>GMS Health Technology Assessment</i> , 2006, 2, Doc08.	2.2	0
269	Screening of the hearing of newborns - Update. <i>GMS Health Technology Assessment</i> , 2006, 2, Doc20.	2.2	3
270	Orchiectomy versus medical therapy with LH-RH analogues for the treatment of advanced prostatic carcinoma. <i>GMS Health Technology Assessment</i> , 2006, 2, Doc13.	2.2	2

#	ARTICLE	IF	CITATIONS
271	Cost effectiveness of haemophilia treatment: a cross-national assessment. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 477-485.	0.5	40
272	Cost of Parkinson's disease in Europe. <i>European Journal of Neurology</i> , 2005, 12, 68-73.	1.7	60
273	Application, Feasibility, and Efficacy of a Combined Intravascular Ultrasound and Stent Delivery System: Results from a Prospective Multicenter Trial. <i>Journal of Interventional Cardiology</i> , 2005, 18, 367-374.	0.5	0
274	Three-Year Clinical Follow-Up After Strontium-90/Yttrium-90 Beta-Irradiation for the Treatment of In-Stent Coronary Restenosis. <i>American Journal of Cardiology</i> , 2005, 96, 1399-1403.	0.7	22
275	Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis. <i>BMC Public Health</i> , 2005, 5, 12.	1.2	24
276	The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stress echocardiography. <i>Clinical Research in Cardiology</i> , 2005, 94, 321-327.	1.2	14
277	Development and evaluation of the Parkinson Psychosis Questionnaire. <i>Journal of Neurology</i> , 2005, 252, 1060-1066.	1.8	53
278	Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon $\alpha$ -2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 112-123.	1.4	18
279	Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis. <i>Heart</i> , 2005, 91, 203-206.	1.2	41
280	Critical Limb Ischemia: Hybrid MR Angiography Compared with DSA. <i>Radiology</i> , 2005, 235, 308-318.	3.6	94
281	Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 55-65.	0.2	38
282	Prevalence and incidence of Parkinson's disease in Europe. <i>European Neuropsychopharmacology</i> , 2005, 15, 473-490.	0.3	461
283	MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS. <i>Value in Health</i> , 2005, 8, A17.	0.1	0
284	PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT. <i>Value in Health</i> , 2005, 8, A123.	0.1	0
285	Discrepancy between morphologic and functional criteria of optimal stent deployment using intravascular ultrasound and pressure derived myocardial fractional flow reserve. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 101-107.	0.5	7
286	Cost of Illness and its Predictors for Parkinson's Disease in Germany. <i>Pharmacoeconomics</i> , 2005, 23, 817-836.	1.7	125
287	Sirolimus-eluting stent implantation and $\beta$ -irradiation for the treatment of in-stent restenotic lesions: Comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. <i>American Heart Journal</i> , 2005, 150, 351-357.	1.2	15
288	Cost-effectiveness Analysis in the Assessment of Diagnostic Imaging Technologies. <i>Radiology</i> , 2005, 235, 361-370.	3.6	71

#	ARTICLE	IF	CITATIONS
289	Antiviral treatment initiation costs in chronic hepatitis C. <i>Gut</i> , 2005, 54, 172-3.	6.1	5
290	Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system. <i>GMS Health Technology Assessment</i> , 2005, 1, Doc03.	2.2	3
291	Influence of tumor necrosis factor $\hat{\pm}$ in rheumatoid arthritis. <i>GMS Health Technology Assessment</i> , 2005, 1, Doc12.	2.2	3
292	The Socioeconomic Impact of Narcolepsy. <i>Sleep</i> , 2004, 27, 1123-1128.	0.6	77
293	Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients ? The IMPROVED multi-centre study. <i>European Heart Journal</i> , 2004, 25, 1626-1634.	1.0	56
294	Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1079-1084.	0.5	169
295	Long-Term Patency of Internal Mammary Artery Bypass Grafts: Relationship With Preoperative Severity of the Native Coronary Artery Stenosis. <i>Circulation</i> , 2004, 110, II-36-II-40.	1.6	90
296	Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. <i>Annals of Oncology</i> , 2004, 15, 863-869.	0.6	71
297	Comparison of pressure measurement, dobutamine contrast stress echocardiography and SPECT for the evaluation of intermediate coronary stenoses. The COMPRESS trial. <i>International Journal of Cardiovascular Interventions</i> , 2004, 6, 142-147.	0.5	26
298	Resource Utilization and Costs of Stroke Unit Care in Germany. <i>Value in Health</i> , 2004, 7, 144-152.	0.1	67
299	Systematic Assessment of Decision Models in Parkinson's Disease. <i>Value in Health</i> , 2004, 7, 610-626.	0.1	23
300	Evolution of angiographic restenosis rate and late lumen loss after intracoronary beta radiation for In-Stent restenotic lesions. <i>American Journal of Cardiology</i> , 2004, 93, 836-842.	0.7	19
301	Comparison of acute and long-term results and underlying mechanisms from sirolimus-eluting stent implantation for the treatment of in-stent restenosis and recurrent in-stent restenosis in patients in whom intracoronary radiation failed as assessed by intravascular ultrasound. <i>American Journal of Cardiology</i> , 2004, 94, 917-921.	0.7	10
302	Cabergoline versus levodopa monotherapy. <i>Movement Disorders</i> , 2004, 19, 733-734.	2.2	2
303	Reply: Cabergoline versus levodopa therapy. <i>Movement Disorders</i> , 2004, 19, 734-736.	2.2	2
304	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	1.7	25
305	Magnetic Resonance Angiography in the Follow-up of Distal Lower-Extremity Bypass Surgery: Comparison with Duplex Ultrasound and Digital Subtraction Angiography. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 1269-1277.	0.2	18
306	PIN6 CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C ADMINISTERED ACCORDING TO THE NEW GENOTYPESPECIFIC GUIDELINES. <i>Value in Health</i> , 2004, 7, 759-760.	0.1	0

#	ARTICLE	IF	CITATIONS
307	PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE" A MULTIVARIATE ANALYSIS. Value in Health, 2004, 7, 793-794.	0.1	0
308	Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve?. American Heart Journal, 2004, 148, 590-595.	1.2	98
309	Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery*. Critical Care Medicine, 2004, 32, 1866-1871.	0.4	41
310	Impact of barotrauma on acute and late angiographic and clinical outcomes following angioplasty and beta-irradiation of coronary in-stent restenotic lesions. Journal of Invasive Cardiology, 2004, 16, 14-9.	0.4	1
311	Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antiviral Therapy, 2004, 9, 27-36.	0.6	9
312	Cost Effectiveness Analysis of Routine Use of Genotypic Antiretroviral Resistance Testing after Failure of Antiretroviral Treatment for HIV. Antiviral Therapy, 2004, 9, 27-36.	0.6	26
313	Superiority of age and weight as variables in predicting osteoporosis in postmenopausal white women. Osteoporosis International, 2003, 14, 950-956.	1.3	45
314	A randomized comparison of 4 doses of intracoronary adenosine in the assessment of fractional flow reserve. Clinical Research in Cardiology, 2003, 92, 627-632.	1.2	11
315	When should decision-analytic modeling be used in the economic evaluation of health care?. European Journal of Health Economics, 2003, 4, 143-150.	1.4	139
316	Cabergoline versus levodopa monotherapy: A decision analysis. Movement Disorders, 2003, 18, 898-905.	2.2	14
317	Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach. Movement Disorders, 2003, 18, S52-S62.	2.2	33
318	Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: A meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheterization and Cardiovascular Interventions, 2003, 59, 314-321.	0.7	90
319	High-resolution MR Imaging of Human Atherosclerotic Femoral Arteries In Vivo: Validation with Intravascular Ultrasound. Journal of Vascular and Interventional Radiology, 2003, 14, 227-231.	0.2	89
320	HP2 THE IMPACT OF TREATMENT MANAGEMENT ALGORITHMS AND EVALUATED TIME HORIZON ON ANTIVIRAL TREATMENT COSTS IN CHRONIC HEPATITIS C. Value in Health, 2003, 6, 608-609.	0.1	0
321	VV6 TRANSFORMING THE UNIFIED PARKINSON'S DISEASE RATING SCALE INTO A UTILITY SCALE. Value in Health, 2003, 6, 611-612.	0.1	1
322	PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA: A DECISION ANALYSIS. Value in Health, 2003, 6, 655-656.	0.1	0
323	PHL3 COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT: A CROSS-NATIONAL ASSESSMENT. Value in Health, 2003, 6, 740.	0.1	0
324	PHL10 ASSESSING PATIENT PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY) OF PROPHYLACTIC HAEMOPHILIA TREATMENT. Value in Health, 2003, 6, 743.	0.1	0

#	ARTICLE	IF	CITATIONS
325	The influence of analytic time horizon and treatment management algorithms on the cost of peginterferon alfa-2b plus ribavirin therapy for chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 173.	1.8	1
326	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. <i>Gut</i> , 2003, 52, 425-432.	6.1	180
327	Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. <i>Aids</i> , 2003, 17, 1521-1529.	1.0	105
328	Economic evaluation of newborn hearing screening: modelling costs and outcomes. <i>GMS German Medical Science</i> , 2003, 1, Doc09.	2.7	8
329	Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment. <i>GMS German Medical Science</i> , 2003, 1, Doc07.	2.7	1
330	The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. <i>Transplantation</i> , 2002, 73, 547-552.	0.5	71
331	Coronary Pressure Measurement After Stenting Predicts Adverse Events at Follow-Up. <i>Circulation</i> , 2002, 105, 2950-2954.	1.6	293
332	UT4 PATIENT-DERIVED UTILITY ESTIMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES. <i>Value in Health</i> , 2002, 5, 460-461.	0.1	0
333	PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS. <i>Value in Health</i> , 2002, 5, 536-537.	0.1	1
334	Cost-effectiveness of peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 129-130.	1.8	0
335	Does health-related quality of life reflect disease severity in chronic hepatitis C patients?. <i>Journal of Hepatology</i> , 2002, 36, 130.	1.8	0
336	Comparison of volumetric intravascular ultrasound analysis of acute results and underlying mechanisms from cutting balloon and conventional balloon angioplasty for the treatment of coronary in-stent restenotic lesions. <i>American Journal of Cardiology</i> , 2002, 90, 539-542.	0.7	11
337	Long-term safety of therapy stratification in patients with intermediate coronary lesions based on intracoronary pressure measurements. <i>American Journal of Cardiology</i> , 2002, 90, 1160-1164.	0.7	34
338	Safety and mechanisms of intracoronary manual stepping brachytherapy as gained from serial angiographic and intravascular ultrasound studies. <i>American Journal of Cardiology</i> , 2002, 90, 1385-1388.	0.7	2
339	Safety of FFR-based treatment strategies: the Munich experience. <i>Clinical Research in Cardiology</i> , 2002, 91, 115-119.	1.2	11
340	Fractional flow reserve predicts major adverse cardiac events after coronary stent implantation. <i>Clinical Research in Cardiology</i> , 2002, 91, 132-136.	1.2	10
341	The role of decision-analytic models in the prevention, diagnosis and treatment of coronary heart disease. <i>Clinical Research in Cardiology</i> , 2002, 91, 144-151.	1.2	8
342	Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. <i>International Angiology</i> , 2002, 21, 305-15.	0.4	40

#	ARTICLE	IF	CITATIONS
343	Demonstration of the healthy worker survivor effect in a cohort of workers in the construction industry. <i>Occupational and Environmental Medicine</i> , 2001, 58, 774-779.	1.3	61
344	Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. <i>American Journal of Cardiology</i> , 2000, 85, 266-269.	0.7	35
345	Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries. <i>American Heart Journal</i> , 2000, 139, 632-637.	1.2	18
346	Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1781-1788.	1.2	102
347	Diagnostic and Prognostic Value of Serial Dobutamine Stress Echocardiography for Noninvasive Assessment of Cardiac Allograft Vasculopathy. <i>Circulation</i> , 1999, 100, 509-515.	1.6	173
348	IVUS analysis of the acute and long-term stent result using motorized pullback: Intraobserver and interobserver variability. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 245-250.	0.7	12
349	PREVENTION OF OSTEOPOROSIS AFTER CARDIAC TRANSPLANTATION. <i>Transplantation</i> , 1999, 68, 523-530.	0.5	67
350	PREDICTORS OF REDUCED CORONARY FLOW RESERVE IN HEART TRANSPLANT RECIPIENTS WITHOUT ANGIOGRAPHICALLY SIGNIFICANT CORONARY ARTERY DISEASE. <i>Transplantation</i> , 1999, 68, 1477-1481.	0.5	13
351	Public-Health-Studium: Bayerischer Public Health L�rwe 1998. <i>Public Health Forum</i> , 1998, 6, 22-22.	0.1	0